

Hannes Hagström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6450604/publications.pdf>

Version: 2024-02-01

102
papers

8,716
citations

101384

36
h-index

46693

89
g-index

102
all docs

102
docs citations

102
times ranked

8021
citing authors

#	ARTICLE	IF	CITATIONS
1	Statins Are Underused in Women With NAFLD After Cardiovascular Events Compared With Matched Control Subjects. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1359-1361.e2.	2.4	3
2	Pregnancy Outcomes in Women With Autoimmune Hepatitis – A Nationwide Population-based Cohort Study With Histopathology. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 103-114.e10.	2.4	6
3	A new model for estimation of significant fibrosis in primary care. SAFE to use?. <i>Hepatology</i> , 2023, 77, 18-19.	3.6	0
4	Three-fold Increased Risk of Death in Budd-Chiari Syndrome Compared to Matched Controls: A Population-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 995-1004.e9.	2.4	1
5	Less is more? Screening for steatosis in older populations. <i>Hepatology</i> , 2023, 77, 350-351.	3.6	1
6	Risk of Cancer in Biopsy-Proven Alcohol-Related Liver Disease: A Population-Based Cohort Study of 3410 Persons. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 918-929.e8.	2.4	24
7	Risk for hepatic and extrahepatic outcomes in nonalcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , 2022, 292, 177-189.	2.7	11
8	Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. <i>Gut</i> , 2022, 71, 1867-1875.	6.1	105
9	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
10	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	1.8	66
11	Risk of infections and their role on subsequent mortality in biopsy-proven alcohol-related liver disease. <i>United European Gastroenterology Journal</i> , 2022, 10, 198-211.	1.6	6
12	Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals. <i>Journal of Internal Medicine</i> , 2022, 291, 824-836.	2.7	26
13	Risk of hepatic and extrahepatic cancer in <scp>NAFLD</scp>: A population-based cohort study. <i>Liver International</i> , 2022, 42, 820-828.	1.9	29
14	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 234-243.	1.9	11
15	Cohort profile: decoding the epidemiology of liver disease in Sweden (DELIVER). <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 978-983.	0.6	12
16	Risk of fractures and subsequent mortality in nonalcoholic fatty liver disease: A nationwide population-based cohort study. <i>Journal of Internal Medicine</i> , 2022, 292, 492-500.	2.7	9
17	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2008-e2020.	1.8	27
18	Risk of cardiovascular disease and loss in life expectancy in NAFLD. <i>Hepatology</i> , 2022, 76, 1495-1505.	3.6	26

#	ARTICLE	IF	CITATIONS
19	The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population-based cohort study. <i>United European Gastroenterology Journal</i> , 2022, 10, 465-476.	1.6	15
20	Nonalcoholic Fatty Liver Disease and Risk of Dementia. <i>Neurology</i> , 2022, 99, .	1.5	28
21	Considerations in the search for under-reported alcohol consumption in NAFLD. <i>Journal of Hepatology</i> , 2022, , .	1.8	2
22	Increased Mortality Risk in Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2636-2647.e13.	2.4	13
23	Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients. <i>Gut</i> , 2021, 70, 170-179.	6.1	49
24	Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. <i>Gut</i> , 2021, 70, 1375-1382.	6.1	307
25	Morbidity, risk of cancer and mortality in 3645 <i>HFE</i> mutations carriers. <i>Liver International</i> , 2021, 41, 545-553.	1.9	11
26	Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden. <i>Clinical Epidemiology</i> , 2021, Volume 13, 21-41.	1.5	111
27	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 437-442.	0.6	4
28	A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 1021-1035.	2.0	23
29	Wide-field endoscopic submucosal dissection for the treatment of Barrett's esophagus neoplasia. <i>Endoscopy International Open</i> , 2021, 09, E727-E734.	0.9	4
30	Etiologies and outcomes of cirrhosis in a large contemporary cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 727-732.	0.6	11
31	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. <i>JHEP Reports</i> , 2021, 3, 100218.	2.6	26
32	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	3.6	102
33	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	8.2	72
34	Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial. <i>JHEP Reports</i> , 2021, 3, 100256.	2.6	87
35	Low Bone Mineral Density and Risk for Osteoporotic Fractures in Patients with Chronic Pancreatitis. <i>Nutrients</i> , 2021, 13, 2386.	1.7	17
36	Maternal obesity increases the risk and severity of NAFLD in offspring. <i>Journal of Hepatology</i> , 2021, 75, 1042-1048.	1.8	41

#	ARTICLE	IF	CITATIONS
37	A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy. <i>Journal of Hepatology</i> , 2021, 75, 98-107.	1.8	25
38	Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. <i>Hepatology</i> , 2021, 74, 2410-2423.	3.6	91
39	Vascular Complications in Patients with Chronic Pancreatitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3720.	1.0	7
40	External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population. <i>JHEP Reports</i> , 2021, 3, 100343.	2.6	2
41	Reply to: "Reduced steatosis and weight as a result of specific diets or the dietitian themselves". <i>JHEP Reports</i> , 2021, 3, 100366.	2.6	0
42	A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1420-1426.	0.8	4
43	Risk of severe COVID-19 and mortality in patients with established chronic liver disease: a nationwide matched cohort study. <i>BMC Gastroenterology</i> , 2021, 21, 439.	0.8	22
44	Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease. <i>Gastroenterology</i> , 2020, 158, 200-214.	0.6	121
45	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1592-1599.e8.	2.4	21
46	Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3720.	1.0	40
47	Bariatric surgery versus standard obesity treatment and the risk of severe liver disease: Data from the Swedish Obese Subjects study. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 2675-2676.e2.	2.4	3
48	Validity of administrative codes associated with cirrhosis in Sweden. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1205-1210.	0.6	43
49	Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1008-1016.	3.7	194
50	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	1.2	2
51	Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1204-1205.	1.9	1
52	Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.3	2
53	Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. <i>Journal of Hepatology</i> , 2020, 73, 1023-1029.	1.8	108
54	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	0.6	575

#	ARTICLE	IF	CITATIONS
55	Incidence of ICD-Based Diagnoses of Alcohol-Related Disorders and Diseases from Swedish Nationwide Registers and Suggestions for Coding. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1433-1442.	1.5	19
56	Transient liver elastography in normal pregnancy – a longitudinal cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 761-765.	0.6	26
57	Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2769-2775.e4.	2.4	37
58	SAT-416-Transient elastography in normal pregnancies: A prospective cohort study. <i>Journal of Hepatology</i> , 2019, 70, e817-e818.	1.8	0
59	The prediction of colorectal cancer using anthropometric measures: A Swedish population-based cohort study with 22 years of follow-up. <i>United European Gastroenterology Journal</i> , 2019, 7, 1250-1260.	1.6	23
60	Association between temperature, sunlight hours and alcohol consumption. <i>PLoS ONE</i> , 2019, 14, e0223312.	1.1	9
61	Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1255.	2.2	58
62	Reply. <i>Hepatology Communications</i> , 2019, 3, 848-848.	2.0	1
63	Is teenage heavy drinking more hazardous than we thought?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 603-605.	1.4	4
64	Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. <i>Liver International</i> , 2019, 39, 1098-1108.	1.9	59
65	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1148-1156.e4.	2.4	71
66	Body mass index in early pregnancy and future risk of severe liver disease: a population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 789-796.	1.9	5
67	Risk Behaviors Associated with Alcohol Consumption Predict Future Severe Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2014-2023.	1.1	10
68	Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. <i>Annals of Internal Medicine</i> , 2019, 171, 318.	2.0	95
69	Predictive Capacity for Mortality and Severe Liver Disease of the Relative Fat Mass Algorithm. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2619-2620.	2.4	13
70	Cardiovascular risk factors in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 197-204.	1.9	75
71	Lifestyle Factors in Late Adolescence Associate With Later Development of Diverticular Disease Requiring Hospitalization. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1474-1480.e1.	2.4	8
72	Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. <i>Liver International</i> , 2018, 38, 2082-2090.	1.9	47

#	ARTICLE	IF	CITATIONS
73	Reply to: "A measure of alcohol consumption in late adolescence associated with liver disease after 39 years of follow-up is insufficient to guide alcohol safe limits" Journal of Hepatology, 2018, 69, 252-253.	1.8	1
74	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatology Communications, 2018, 2, 48-57.	2.0	200
75	Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life. Journal of Hepatology, 2018, 68, 505-510.	1.8	52
76	Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. Digestive Diseases and Sciences, 2018, 63, 1348-1354.	1.1	27
77	High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. Gut, 2018, 67, 1536-1542.	6.1	68
78	Pregnancy outcome in women undergoing liver biopsy during pregnancy: A nationwide population-based cohort study. Hepatology, 2018, 68, 625-633.	3.6	20
79	Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver International, 2018, 38, 885-894.	1.9	25
80	Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies. Hepatology Communications, 2018, 2, 1299-1305.	2.0	56
81	Editorial: severe outcomes are rare in pregnancy with autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2018, 48, 1017-1018.	1.9	2
82	Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up. PLoS ONE, 2018, 13, e0202651.	1.1	11
83	Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Gastroenterology Research and Practice, 2018, 2018, 1-7.	0.7	16
84	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology, 2017, 65, 1557-1565.	3.6	1,294
85	Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1461-1468.	2.4	37
86	Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2017, 15, 1950-1956.e1.	2.4	84
87	Waist/Hip Ratio Better Predicts Development of Severe Liver Disease Within 20 Years Than Body Mass Index: A Population-based Cohort Study. Clinical Gastroenterology and Hepatology, 2017, 15, 1294-1301.e2.	2.4	36
88	Alcohol, smoking and the liver disease patient. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 537-543.	1.0	21
89	IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD – a pilot study. Scandinavian Journal of Gastroenterology, 2017, 52, 1427-1434.	0.6	36
90	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology, 2017, 67, 1265-1273.	1.8	730

#	ARTICLE	IF	CITATIONS
91	Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?. <i>Current Hepatology Reports</i> , 2017, 16, 152-157.	0.4	45
92	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 87-91.	0.6	32
93	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 159-165.	0.6	60
94	Reply. <i>Hepatology</i> , 2016, 64, 310-311.	3.6	0
95	Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. <i>Liver International</i> , 2016, 36, 1688-1695.	1.9	54
96	Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study. <i>Journal of Hepatology</i> , 2016, 65, 363-368.	1.8	68
97	Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 268-274.	1.9	80
98	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. <i>PLoS ONE</i> , 2016, 11, e0167776.	1.1	17
99	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. <i>Hepatology</i> , 2015, 61, 1547-1554.	3.6	1,683
100	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001680.	3.9	507
101	Alcohol consumption in patients with primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2012, 18, 3105.	1.4	17
102	Hepatocellular carcinoma in Stockholm, Sweden 2003–2018: a population-based cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-9.	0.6	0